Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability to date. Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama...